Literature DB >> 20692841

A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis.

Jianhui Wu1, Chunyu Li, Ming Zhao, Wenjing Wang, Yuji Wang, Shiqi Peng.   

Abstract

Based on DOCK scores 18 N-(3-benzyloxycarbonylcarboline-1-yl)ethylamino acid benzylesters (6a-r) were synthesized as anti-tumor agents. Their IC(50) values against five human carcinoma cell lines ranged from 11.1muM to more than 100muM. The in vivo assay identified five derivatives of them had no anti-tumor action, the anti-tumor activity of nine derivatives of them equaled that of cytarabine, and the anti-tumor activity of three derivatives of them was higher than that of cytarabine. The UV and fluorescence spectra, as well as the relative viscosity and melting temperature measurements of calf thymus DNA (CT DNA) with and without the representative compound suggested that DNA intercalation could be their action mechanism. The 3D QSAR analysis of N-(3-benzyloxycarbonylcarboline-1-yl)ethylamino acid benzylesters (6a-r) revealed that their in vivo anti-tumor activity significantly depends on the molecular electrostatic and steric fields of the side chain of the amino acid residue. Crown Copyright 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20692841     DOI: 10.1016/j.bmc.2010.07.043

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.

Authors:  Matteo Incerti; Massimiliano Tognolini; Simonetta Russo; Daniele Pala; Carmine Giorgio; Iftiin Hassan-Mohamed; Roberta Noberini; Elena B Pasquale; Paola Vicini; Silvia Piersanti; Silvia Rivara; Elisabetta Barocelli; Marco Mor; Alessio Lodola
Journal:  J Med Chem       Date:  2013-03-22       Impact factor: 7.446

2.  Manganese dioxide mediated one-pot synthesis of methyl 9H-pyrido[3,4-b]indole-1-carboxylate: Concise synthesis of alangiobussinine.

Authors:  Jessica Baiget; Sabin Llona-Minguez; Stuart Lang; Simon P Mackay; Colin J Suckling; Oliver B Sutcliffe
Journal:  Beilstein J Org Chem       Date:  2011-10-12       Impact factor: 2.883

3.  Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.

Authors:  Wen Zhao; Yifan Zhang; Xueyun Jiang; Chunying Cui
Journal:  Drug Des Devel Ther       Date:  2016-11-24       Impact factor: 4.162

4.  N-(3-hydroxymethyl-β-carboline-1-yl-ethyl- 2-yl)-l-Phe: development toward a nanoscaled antitumor drug capable of treating complicated thrombosis and inflammation.

Authors:  Jianhui Wu; Ming Zhao; Yuji Wang; Yaonan Wang; Haimei Zhu; Shurui Zhao; Lin Gui; Xiaoyi Zhang; Shiqi Peng
Journal:  Drug Des Devel Ther       Date:  2017-01-17       Impact factor: 4.162

5.  Synthesis and evaluation of new β-carboline-3-(4-benzylidene)-4H-oxazol-5-one derivatives as antitumor agents.

Authors:  Franciele Cristina Savariz; Mary Ann Foglio; João Ernesto de Carvalho; Ana Lúcia T G Ruiz; Marta C T Duarte; Mauricio Ferreira da Rosa; Emerson Meyer; Maria Helena Sarragiotto
Journal:  Molecules       Date:  2012-05-21       Impact factor: 4.411

6.  Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine.

Authors:  Xiaoyi Zhang; Yixin Zhang; Yaonan Wang; Jianhui Wu; Haiyan Chen; Ming Zhao; Shiqi Peng
Journal:  Int J Nanomedicine       Date:  2020-01-21

7.  Docking of THPDTPI: to explore P-selectin as a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent.

Authors:  Haimei Zhu; Yuji Wang; Ce Song; Qiqi Feng; Jianhui Wu; Shurui Zhao; Lin Gui; Xiaoyi Zhang; Ming Zhao; Shiqi Peng
Journal:  Oncotarget       Date:  2017-07-19

8.  Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors.

Authors:  Haiyan Chen; An Lu; Xiaoyi Zhang; Lin Gui; Yaonan Wang; Jianhui Wu; Hua Feng; Shiqi Peng; Ming Zhao
Journal:  Drug Des Devel Ther       Date:  2018-07-09       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.